[68Ga]Ga-FAPI-04 PET/CT在对[177Lu]Lu-DOTATATE难治性高分化神经内分泌肿瘤中作为诊断和治疗诊断生物标志物的较差表现
研究纳入12例接受至少两周期[177Lu]Lu-DOTATATE治疗后进展的转移性神经内分泌肿瘤患者,均在3周内完成[68Ga]Ga-DOTATATE与[68Ga]Ga-FAPI-04 PET/CT。230个病灶中SSTR阳性198个(86%)、FAPI阳性88个(38.2%),[68Ga]Ga-DOTATATE PET/CT中位SUVmax及检出肿瘤数显著更高(p<0.001)。初步结果表明[68Ga]Ga-FAPI-04 PET/CT在高分化NET中主要表现不佳,作为替代诊断或治疗诊断剂作用有限,需更大样本进一步研究。
要点
- 230个NET相关病灶中[68Ga]Ga-DOTATATE阳性198个(86%),[68Ga]Ga-FAPI-04阳性88个(38.2%)。
- [68Ga]Ga-DOTATATE中位SUVmax 16.6(2.2-76.5)vs [68Ga]Ga-FAPI-04 5.1(2.3-21),前者显著更高(p<0.001)。
- 5例(42%)患者[68Ga]Ga-FAPI-04 PET/CT完全(2例)或几乎完全(3例)阴性。
核心结论
- 初步结果表明[68Ga]Ga-FAPI-04 PET/CT在对[177Lu]Lu-DOTATATE难治性高分化NET中主要表现不佳,作为替代诊断或治疗诊断剂作用有限。
- 需要更大患者人群的进一步研究来确定[68Ga]Ga-FAPI-04 PET/CT对NET的影响。
研究设计与样本
- 纳入接受至少两周期[177Lu]Lu-DOTATATE治疗用于转移性NET且治疗中进展的患者。
- 所有患者均在3周内完成[68Ga]Ga-DOTATATE与[68Ga]Ga-FAPI-04 PET/CT。
- 记录NET相关PET阳性病灶数和肿瘤部位,采用Mann-Whitney U检验和卡方检验比较示踪剂SUVmax水平及检出转移灶数量。
- 共纳入12例符合标准患者(7男、5女);10例为不同来源的1-2级NET,2例分别为副神经节瘤和嗜铬细胞瘤。
主要发现
- 230个病灶中198个(86%)SSTR阳性,中位SUVmax 16.6(2.2-76.5);88个(38.2%)[68Ga]Ga-FAPI-04阳性,中位SUVmax 5.1(2.3-21)。
- [68Ga]Ga-DOTATATE PET/CT的中位SUVmax水平和检出肿瘤数量显著高于[68Ga]Ga-FAPI-04 PET/CT(p<0.001)。
- 5例(42%)患者[68Ga]Ga-FAPI-04 PET/CT完全阴性(2例)或几乎完全阴性(3例)。
- 2例(17%)患者肿瘤中出现SSTR/FAPI摄取的翻转现象。
- 4例(33%)患者[68Ga]Ga-FAPI-04 PET/CT的肿瘤摄取或PET阳性病灶数较低;仅1例(8%)患者[68Ga]Ga-FAPI-04 PET/CT肿瘤摄取较高。
关键数值与推荐
- FAPI优势患者接受低剂量[177Lu]Lu-FAPI-46剂量学测定,每GBq吸收辐射剂量肾脏1.26 Gy、肝脏0.36 Gy、脾脏0.32 Gy、全身0.2 Gy。
- 每GBq平均吸收剂量肝脏肿块为0.33 Gy,转移淋巴结为0.41 Gy。
临床怎么用
- 原文未据此给出推荐。
局限性
- 结论称本研究为初步结果。
- 原文指出需要更大患者人群的进一步研究来确定[68Ga]Ga-FAPI-04 PET/CT对NET的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to investigate the potential of [68Ga]Ga-FAPI-04 PET/CT as an alternative diagnostic and theranostic tool in well-differentiated NETs refractory to [177Lu]Lu-DOTATATE therapy. METHODS: Patients who received at least two cycles of [177Lu]Lu-DOTATATE therapy for metastatic NETs and progressed under treatment were included. All patients had performed [68Ga]Ga-DOTATATE and [68Ga]Ga-FAPI-04 PET/CT within 3 weeks. The number of PET-positive lesions related to NETs and tumor sites was documented. Mann-Whitney U and chi-square tests were used to compare SUVmax levels of tracers and the number of detected metastases. RESULTS: Twelve patients (7 male, 5 female) who met the eligibility criteria were included in the study. Ten patients had grade 1-2 NET of various origins, and two had paraganglioma and pheochromocytoma. One hundred ninety-eight of 230 lesions (86%) were SSTR positive with a median SUVmax of 16.6 (2.2-76.5), and 88 of 230 lesions (38.2%) were [68Ga]Ga-FAPI-04 positive with a median SUVmax of 5.1 (2.3-21). Median SUVmax level and detected number of tumors were significantly higher in [68Ga]Ga-DOTATATE PET/CT (p=<0.001). [68Ga]Ga-FAPI-04 PET/CT was completely (n:2) or almost completely (n:3) negative in 5 (42%) patients. Two (17%) patients had flip-flop SSTR/FAPI uptake in tumors. In four patients (33%), tumor uptake or the number of PET-positive lesions was inferior in [68Ga]Ga-FAPI-04 PET/CT. In only one patient (8%), tumor uptakes were higher in [68Ga]Ga-FAPI-04 PET/CT. Low-dose [177Lu]Lu-FAPI-46 dosimetry was performed on the FAPI-dominant patient; absorbed radiation doses per GBq were 1.26 Gy, 0.36 Gy, 0.32 Gy, and 0.2 Gy for kidneys, liver, spleen, and total body, respectively. The mean absorbed dose per GBq was 0.33 Gy for liver mass and 0.41 Gy for metastatic lymph nodes. CONCLUSION: Our preliminary results demonstrated that [68Ga]Ga-FAPI-04 PET/CT mainly failed in well-differentiated NETs refractory to [177Lu]Lu-DOTATATE therapy and had a limited role as an alternative diagnostic or theranostic agent. Further investigations with a larger patient population are required to determine the impact of [68Ga]Ga-FAPI-04 PET/CT on NETs.
引用
- Has Simsek D, Guzel Y, Denizmen D, et al. The inferior performance of [68Ga]Ga-FAPI-04 PET/CT as a diagnostic and theranostic biomarker in [177Lu]Lu-DOTATATE refractory well-differentiated neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2023. PMID: 37947850. doi:10.1007/s00259-023-06497-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。